ABSTRACTT-cell-engaging bispecific antibodies (T-bsAbs) are promising immunotherapies for cancer treatment due to their capability of redirecting T-cells toward destroying tumor cells. Numerous T-bsAb formats have been developed, each with advantages and disadvantages in terms of developability, immunogenicity, effector functions, and pharmacokinetics. Here, we systematically compared T-bsAbs produced using eight different formats, evaluating the effect of molecular design of T-bsAbs on their manufacturability and functionality. These eight T-bsAb formats were constructed using antigen-binding fragments (Fabs) and single-chain variable fragments (scFvs) of antibodies linked to the crystallizable fragment (Fc) domain of immunoglobulin G. To ...
T cell engager (TCE) antibodies have emerged as promising cancer therapeutics that link cytotoxic T-...
With the development of molecular cloning technology and the deep understanding of antibody engineer...
Bispecific antibodies that engage immune cells to kill cancer cells have been actively studied in ca...
Abstract Since the advances in protein engineering and manufacture, over the last 30 years, antibody...
Due to the technical innovations in generating bispecific antibodies (BsAbs) in recent years, BsAbs ...
In the era of immunotherapeutic control of cancers, many advances in biotechnology, especially in Ab...
A myriad of innovative bispecific antibody (BsAb) platforms have been reported. Most require signifi...
Bispecific antibodies (BsAbs) are a sort of dual functional proteins with specific binding to two di...
Bispecific antibodies (BsAb) are promising therapeutic tools in tomorrow's medicine. When constructi...
International audienceWe have designed and validated a novel generic platform for production of tetr...
Bispecific antibodies (BsAbs) for T cell engagement have shown great promise in cancer immunotherapy...
We have designed and validated a novel generic platform for production of tetravalent IgG1-like chim...
The term bispecific antibody (bsAb) is used to describe a large family of molecules designed to reco...
We report the construction, expression and purification of a bispecific single-chain Fv antibody fra...
Bi-specific T-cell engager antibodies (BiTEs) are synthetic fusion molecules that combine multiple a...
T cell engager (TCE) antibodies have emerged as promising cancer therapeutics that link cytotoxic T-...
With the development of molecular cloning technology and the deep understanding of antibody engineer...
Bispecific antibodies that engage immune cells to kill cancer cells have been actively studied in ca...
Abstract Since the advances in protein engineering and manufacture, over the last 30 years, antibody...
Due to the technical innovations in generating bispecific antibodies (BsAbs) in recent years, BsAbs ...
In the era of immunotherapeutic control of cancers, many advances in biotechnology, especially in Ab...
A myriad of innovative bispecific antibody (BsAb) platforms have been reported. Most require signifi...
Bispecific antibodies (BsAbs) are a sort of dual functional proteins with specific binding to two di...
Bispecific antibodies (BsAb) are promising therapeutic tools in tomorrow's medicine. When constructi...
International audienceWe have designed and validated a novel generic platform for production of tetr...
Bispecific antibodies (BsAbs) for T cell engagement have shown great promise in cancer immunotherapy...
We have designed and validated a novel generic platform for production of tetravalent IgG1-like chim...
The term bispecific antibody (bsAb) is used to describe a large family of molecules designed to reco...
We report the construction, expression and purification of a bispecific single-chain Fv antibody fra...
Bi-specific T-cell engager antibodies (BiTEs) are synthetic fusion molecules that combine multiple a...
T cell engager (TCE) antibodies have emerged as promising cancer therapeutics that link cytotoxic T-...
With the development of molecular cloning technology and the deep understanding of antibody engineer...
Bispecific antibodies that engage immune cells to kill cancer cells have been actively studied in ca...